New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment
August 7, 2010 by admin · Leave a Comment
INDIANAPOLIS Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.
Discovery of a hepatitis C-related virus in bats may reduce outbreaks in humans
July 1, 2010 by admin · Leave a Comment
July 1, 2010 — Viral hepatitis affects more than 500 million people worldwide and is a cause of liver failure and liver cancer. While vaccines are available for hepatitis A and B, this is not the case for hepatitis C, which affects as much as two percent of the population in the U.S. Scientists today are reporting discovery of a virus related to hepatitis C in Asian bats, which may provide insights into the origins of the hepatitis C virus and into the mechanisms by which infectious diseases move from other species to humans.
Silencing hepatitis B virus prevent recurrence of liver cancer
June 23, 2010 by admin · Leave a Comment
(PHILADELPHIA) Previous studies have shown that antiviral treatment reduces the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). But now, researchers from the Division of Gastroenterology and Hepatology at Thomas Jefferson University are reporting that the antiviral therapy also prevents recurrence of HCC and extends patients’ lives.
A nutritional supplement for treating chronic hepatitis C: Viusid
June 16, 2010 by admin · Leave a Comment
The pathogenesis of chronic hepatitis C (CHC) is associated with severe oxidative stress and non-selective immunological disturbance that lead to necroinflammation and the progression of fibrosis. Several trials have suggested that antioxidant and immunostimulant therapies may have a beneficial effect. Two previous clinical studies have reported that the Viusid related effect on histologic features, especially fibrosis, appears to be associated with antioxidant and/or immunomodulatory properties. However, the putative mechanism of action of Viusid is unknown.
Small genetic variant can predict response to hepatitis C treatment
June 11, 2010 by admin · Leave a Comment
Contact: Mary Rice
mary@mrcommunication.org
European Society of Human Genetics Read more
New use for old drugs in treating hepatitis C
June 6, 2010 by admin · Leave a Comment
Common drugs used to treat conditions such as diabetes and obesity could be used to successfully treat hepatitis C virus infection.
Research led by the University of Leeds has found drugs such as anti-diabetic drug Metformin and AICAR, used to combat obesity, can prevent the hepatitis C virus from replicating in the body.
Combination of direct antivirals may be key to curing hep C
May 4, 2010 by admin · Leave a Comment
Contact: Sherri McGinnis González
smcginn@uic.edu
312-996-8277
University of Illinois at Chicago
A combination of antiviral drugs may be needed to combat the drug resistance that rapidly develops in potentially deadly hepatitis C infections, a new study using sophisticated computer and mathematical modeling has shown.
Some patients with hepatitis B faring better after liver transplant
May 3, 2010 by admin · Leave a Comment
Contact: Ginger Plumbo
newsbureau@mayo.edu
507-284-5005
Mayo Clinic Read more
New drug treatments hold promise for Crohn’s disease and hepatitis C patients
May 3, 2010 by admin · Leave a Comment
Contact: Amy Levey
alevey@gymr.com
202-745-5116
Digestive Disease Week
Health outcomes explored at DDW 2010
Extended hepatitis C treatment after liver transplant may benefit patients
May 1, 2010 by admin · Leave a Comment
Contact: Maria Seyrig
mseyrig1@hfhs.org
313-874-4039
Henry Ford Health System
DETROIT Extending hepatitis C treatment for liver transplant patients beyond current standards results in high clearance rates of the hepatitis C virus from the blood, and a low relapse rate, according to a study by Henry Ford Hospital.
